DarioHealth Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
45.2%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$21.7Mnext fiscal year
FY EPS (est.)
-$2.47next fiscal year
Monitoring Framework
Key Performance Indicators
B2B2C Non-GAAP Gross Margin Quarterly80.0%Target: Sustain at or above 80%
Commercial Pipeline Value Quarterly127MTarget: Continued expansion and conversion
Covered Lives Reach Quarterly116MTarget: Increase active user conversion rate
Watch Items
- Conversion of 2025-signed ARR contracts to recognized revenueTrigger: Delays in onboarding or lower-than-expected conversion of the $12.9M ARRAction: Re-evaluate commercial execution, client onboarding workflows, and near-term revenue guidance
- Cash burn rate and path to cash flow breakevenTrigger: Failure to narrow operating losses sequentially or delay of breakeven target past mid-2027Action: Implement further operational efficiency measures and review capital allocation
Research as of 19 Jun 2026